



# Balfour Capital Group Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a leading American biotechnology company headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron specializes in inventing, developing, manufacturing, and commercializing medicines for serious diseases. The company has developed several notable drugs, including:

- Eylea: A treatment for eye diseases such as macular degeneration.
- Dupixent: An anti-inflammatory drug developed in collaboration with Sanofi.
- Libtayo: A treatment for certain types of skin cancer.

Regeneron utilizes proprietary technologies like VelociSuite to accelerate drug discovery and development.

## 1. Top 5 Competitors

Regeneron's primary competitors in the biotechnology and pharmaceutical sectors include:

1. Amgen
2. Novartis
3. Roche
4. AbbVie
5. Sanofi

These companies compete with Regeneron in various therapeutic areas, including oncology, immunology, and ophthalmology.

## 2. Largest Institutional Shareholders

As of the latest filings, the largest institutional shareholders of Regeneron are:

- Vanguard Group Inc.: Holding shares valued at approximately \$6.61 billion.
- BlackRock Inc.: Holding shares valued at approximately \$6.53 billion.
- FMR LLC: Holding shares valued at approximately \$5.84 billion.
- State Street Corp: Holding shares valued at approximately \$5.15 billion.
- Capital International Investors: Holding shares valued at approximately \$3.37 billion.



# Balfour Capital Group Regeneron Pharmaceuticals, Inc.

## 3. Management Team:

Key members of Regeneron's management team include:

- Leonard S. Schleifer, MD, PhD: Founder, President, and Chief Executive Officer.
- George D. Yancopoulos, MD, PhD: Co-Founder, President, and Chief Scientific Officer.
- Robert E. Landry: Executive Vice President, Finance, and Chief Financial Officer.
- Joseph J. LaRosa: Executive Vice President, General Counsel, and Secretary.

## 4. Revenue

- In 2024, Regeneron reported total revenues of \$14.2 billion, representing an 8% increase from the previous year.

## 5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for Regeneron, including:

- Leerink Partners: Maintained an "Outperform" rating, citing strong performance of Dupixent.
- J.P. Morgan: Highlighted the strength of Dupixent in offsetting challenges with Eylea.

## 6. Summary of Analyst Sentiment:

Analyst sentiment toward Regeneron is generally positive:

- Consensus Rating: "Strong Buy" based on 26 analyst ratings.
- Average Price Target: Approximately \$892.60, indicating potential upside from the current stock price.

## 7. Insider Buying and Selling Over the Last 24 Months:

Over the past 24 months, Regeneron insiders have sold a total of 144,104 shares, amounting to approximately \$135.7 million. There have been no significant insider purchases reported during this period.